Recent Updates — BGLC

BioNexus Gene Lab Corp entered into a strategic collaboration agreement with Ruanyun Edai Technology Inc. to secure an exclusive ten-year licence for the CogniAI document-intelligence platform within Malaysia's healthcare sector. At closing, BioNexus will issue 410,000 common shares valued at US$3.5 million and another 150,000 shares in exchange for 500,000 RYET ordinary shares. The deal includes a 10% royalty on collected technology receipts and allows BioNexus to expand into other Malaysian industries. Closing is pending regulatory approvals and technology acceptance by March 31, 2027. BioNexus Gene Lab Corp operates in biotechnology, precision diagnostics, and specialty materials.

BioNexus Gene Lab Corp. issued a press release detailing progress in commercializing its VitaGuard™ molecular residual disease (MRD) platform in Southeast Asia. The announcement follows a working visit by Fidelion Diagnostics’ Chief Commercial Officer to Tongshu Gene facilities in Shanghai and Changzhou, China, where the platform is in paid commercial use. BioNexus holds exclusive rights to the platform in ten Southeast Asian markets and owns approximately 15% of Fidelion. The company targets initial deployment in Malaysia and Singapore during 2026, pending regulatory approvals and laboratory validation. BioNexus Gene Lab Corp. operates in the biotechnology and precision diagnostics industry, developing healthcare technologies and specialty materials.